JP7385206B2 - 免疫賦活剤 - Google Patents
免疫賦活剤 Download PDFInfo
- Publication number
- JP7385206B2 JP7385206B2 JP2018227061A JP2018227061A JP7385206B2 JP 7385206 B2 JP7385206 B2 JP 7385206B2 JP 2018227061 A JP2018227061 A JP 2018227061A JP 2018227061 A JP2018227061 A JP 2018227061A JP 7385206 B2 JP7385206 B2 JP 7385206B2
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- lipid particles
- antigen
- test example
- immunostimulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003308 immunostimulating effect Effects 0.000 title claims description 76
- 229960001438 immunostimulant agent Drugs 0.000 title claims description 38
- 239000003022 immunostimulating agent Substances 0.000 title claims description 36
- 239000002245 particle Substances 0.000 claims description 123
- 150000002632 lipids Chemical class 0.000 claims description 114
- -1 cationic lipid Chemical class 0.000 claims description 78
- 239000000427 antigen Substances 0.000 claims description 66
- 102000036639 antigens Human genes 0.000 claims description 66
- 108091007433 antigens Proteins 0.000 claims description 66
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 37
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 23
- 229960005486 vaccine Drugs 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims description 7
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 claims description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 73
- 108010058846 Ovalbumin Proteins 0.000 description 38
- 229940092253 ovalbumin Drugs 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- 239000002585 base Substances 0.000 description 21
- 230000001939 inductive effect Effects 0.000 description 18
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 102100037850 Interferon gamma Human genes 0.000 description 16
- 108010074328 Interferon-gamma Proteins 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 125000002091 cationic group Chemical group 0.000 description 9
- 229940037003 alum Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
- 230000007969 cellular immunity Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- 230000005934 immune activation Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010019759 OVA 323-339 Proteins 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- QNPBWACMHMATDF-WRBBJXAJSA-N (9z,29z)-19-[(dimethylamino)methyl]-20-(2-hydroxyethylamino)octatriaconta-9,29-diene-18,21-dione Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)C(CN(C)C)C(NCCO)C(=O)CCCCCCC\C=C/CCCCCCCC QNPBWACMHMATDF-WRBBJXAJSA-N 0.000 description 1
- UYHAERNXVVKSCT-PGUFJCEWSA-N 1,2-dipalmitoyl-sn-glycero-3-phosphoethanol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCCCCCCCCC UYHAERNXVVKSCT-PGUFJCEWSA-N 0.000 description 1
- RUAUPNFNQOGIFF-UHFFFAOYSA-N 1-(4-tert-butyl-2,5-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC(C(C)(C)C)=C(OC)C=C1CC(C)N RUAUPNFNQOGIFF-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- FJUOBOJIJWDANZ-UHFFFAOYSA-N 2-[(4-anilinophenyl)iminomethyl]-5-(diethylamino)phenol Chemical compound CCN(CC)C1=CC(=C(C=C1)C=NC2=CC=C(C=C2)NC3=CC=CC=C3)O FJUOBOJIJWDANZ-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000484121 Human parvovirus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108010048684 O,O'-dimyristyl-N-lysyl aspartate Proteins 0.000 description 1
- 108010047807 O,O'-dimyristyl-N-lysyl glutamate Proteins 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000012839 cake mixes Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- AJOVHKRJQWSZLE-PXLJZGITSA-N ditetradecyl (2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]butanedioate Chemical compound CCCCCCCCCCCCCCOC(=O)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)OCCCCCCCCCCCCCC AJOVHKRJQWSZLE-PXLJZGITSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- MCIDNMJNWYUTMB-UHFFFAOYSA-N n-tert-butyl-n'-tetradecyl-3-(tetradecylamino)propanimidamide Chemical compound CCCCCCCCCCCCCCNCCC(NC(C)(C)C)=NCCCCCCCCCCCCCC MCIDNMJNWYUTMB-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- NRWCNEBHECBWRJ-UHFFFAOYSA-M trimethyl(propyl)azanium;chloride Chemical compound [Cl-].CCC[N+](C)(C)C NRWCNEBHECBWRJ-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
(B)粒径100nm未満のカチオン性脂質含有脂質粒子bを含有する、
免疫賦活剤。
本発明は、その一態様において、(A)カチオン性脂質含有脂質粒子a、並びにCpGオリゴデオキシヌクレオチド及びアルミニウム塩からなる群より選択される少なくとも1種を含有する、又は(B)粒径100nm未満のカチオン性脂質含有脂質粒子bを含有する、免疫賦活剤(本明細書において、「本発明の免疫賦活剤」と示すこともある。)に係る。以下に、これについて説明する。
本発明の免疫賦活剤は、細胞性免疫の誘導作用(特に、CD8T細胞誘導作用及び/又はCD4T細胞誘導作用)(例えばIFN-γ誘導作用)をより高く発揮することができる。さらには、抗体誘導能をもより高く発揮することも可能である。このため、本発明の免疫賦活剤は、その免疫賦活作用を利用した種々の用途、例えば医薬、試薬等(本明細書において、「本発明の薬剤」と示すこともある。)に、より具体的には、ワクチン組成物、抗ウイルス用薬剤等に利用が可能である。
カチオン性脂質含有脂質粒子の免疫賦活作用を調べた。具体的には以下のようにして行った。
溶質としてDOTAP(Lipoid社)のみを含有(DOTAP濃度1.0質量%)するエタノール溶液と25mM Sodium Acetate(pH4.0)とを、NanoAssemblr(Precision NanoSystems社製)を用いて1:3(エタノール溶液:Sodium Acetate、混合比)、15 mL/minで混合してリピッドナノ粒子(Lipid nanoparticle:LNP)化し、透析(5%グルコース水溶液)を行い、脂質粒子(DOTAP(037)又はDOTAP-Nano(037))を得た。
脂質粒子(DOTAP-Nano(037)又はDOTAP-Roche)と、抗原としてclassII 応答(CD4T細胞)を誘導するOVA(オボアルブミン)とを10:1(脂質:抗原、質量比)で混合してワクチン組成物を調製した。得られたワクチン組成物を、マウスの皮下(尻尾の付け根)に免疫(1匹あたり、脂質100ug)した。7日後に脾臓細胞を回収し、classI 応答(CD8T細胞)を誘導する257-264ペプチド(Eurofins社製)257-264ペプチド、又はOVAで刺激し、1日後の細胞上清中のIFN-γ量をELISA法で定量した。
粒径が異なる2種類のカチオン性脂質含有脂質粒子の免疫賦活作用を調べた。具体的には以下のようにして行った。
試験例1-1と同一条件で脂質粒子(DOTAP-Nano(041))を得た。
DOTAP Liposomal Transfection Reagent(Roche社製)を脂質粒子(DOTAPのみから構成される粒子)を使用した。この脂質粒子は、MES(2-(N-morpholino)ethanesulfonic acid)緩衝液(pH6.3)中で調製されているので、この脂質粒子の緩衝液をDOTAP-Nanoと同じ緩衝液(PBS)に置換して、使用した(DOTAP-Roche)。
DOTAP-Nano(041)とDOTAP-Rocheの粒径(散乱光強度基準)を動的光散乱(DLS)法により測定した。さらに、これらの脂質粒子とモデルワクチン抗原であるOVAとを10:1(脂質:OVA、質量比)で混合した後、同様して動的光散乱(DLS)法により測定した。
刺激に257-264ペプチド(classI 応答(CD8T細胞)を誘導)のみを使用する以外は、試験例1-2と同様にして行った。
粒径が異なる3種類のカチオン性脂質含有脂質粒子の免疫賦活作用を調べた。具体的には以下のようにして行った。
1:2(エタノール溶液:Sodium Acetate、混合比)、12 mL/min以外は、試験例1-1と同一条件で脂質粒子(DOTAP-Nano(050))を得た。試験例2-3と同様にして粒径を測定した結果、その粒径は50nmであった。
1:3(エタノール溶液:Sodium Acetate、混合比)、12 mL/min以外は、試験例1-1と同一条件で脂質粒子(DOTAP-Nano(051))を得た。試験例2-3と同様にして粒径を測定した結果、その粒径は30nmであった。
1:4(エタノール溶液:Sodium Acetate、混合比)、12 mL/min以外は、試験例1-1と同一条件で脂質粒子(DOTAP-Nano(052))を得た。試験例2-3と同様にして粒径を測定した結果、その粒径は20nmであった。
刺激に257-264ペプチド(classI 応答(CD8T細胞)を誘導)のみを使用する以外は、試験例1-2と同様にして行った。
脂質粒子にCpG核酸を組み合わせた場合の免疫賦活作用を調べた。具体的には以下のようにして行った。
脂質粒子にCpG核酸を組み合わせ、さらにアルミニウム塩を組合せた場合の免疫賦活作用を調べた。具体的には以下のようにして行った。
脂質粒子(DOTAP-Nano(037))、CpG核酸(A型(D35))、アルミニウム塩(水酸化アルミニウム)、及び抗原としてOVAを10:1:4:1(脂質:CpG核酸:アルミニウム塩:抗原、質量比)で混合してワクチン組成物を調製した以外は、試験例1-2と同様にして免疫賦活試験を行った。
試験例5-1において、免疫から7日後に血清を回収し、OVAに対する抗体価をELISA法で定量した。
アルミニウム塩として水酸化アルミニウム以外にもリン酸化アルミニウムを使用する以外は、試験例5-1と同様にして行った。その結果、いずれのアルミニウム塩を使用した場合でも、免疫賦活作用は同程度であることが分かった。
アジュバントとして脂質粒子(DOTAP-Nano(037))又は水酸化アルミニウムと、抗原としてclassII 応答(CD4T細胞)を誘導するインフルエンザウイルススプリットワクチン抗原とを100:0.04(アジュバント:抗原、質量比)で混合してワクチン組成物を調製した。得られたワクチン組成物を、マウスの皮下(尻尾の付け根)に免疫(1匹あたり、アジュバント100ug)した。7日後に脾臓細胞を回収し、インフルエンザウイルススプリットワクチン抗原で刺激し、1日後の細胞上清中のIFN-γ量をELISA法で定量した。
アジュバントとして脂質粒子(DOTAP-Nano(037))、CpG核酸(A型(D35))、又は水酸化アルミニウムと、抗原としてHHV-6Bとを100:10(アジュバント:抗原、質量比)で混合してワクチン組成物を調製した。得られたワクチン組成物を、マウスの皮下(尻尾の付け根)に免疫(1匹あたり、アジュバント100ug)した。7日後に脾臓細胞を回収し、p43ペプチドで刺激し、1日後の細胞上清中のIFN-γ量をELISA法で定量した。
Claims (10)
- (A)カチオン性脂質含有脂質粒子a、CpGオリゴデオキシヌクレオチド、及びアルミニウム塩を含有する、
免疫賦活剤。 - 前記カチオン性脂質含有脂質粒子aがナノサイズである、請求項1に記載の免疫賦活剤。
- 前記カチオン性脂質が1,2-ジオレオイルオキシ-3-トリメチルアンモニウム-プロパン(DOTAP)、ジオレオイルジメチルアミノプロパン(DODAP)、N-1-(2,3-ジオレオイルオキシ)プロピル-N,N,N-トリメチルアンモニウムクロリド(DOTMA)、及びジメチルジオクタデシルアンモニウムブロミド(DDAB)からなる群より選択される少なくとも1種である、請求項1又は2に記載の免疫賦活剤。
- 前記カチオン性脂質の含有量が、前記脂質粒子を構成する脂質100質量%に対して80質量%以上である、請求項1~3のいずれかに記載の免疫賦活剤。
- 前記カチオン性脂質の含有量が、前記脂質粒子を構成する脂質100質量%に対して95質量%以上である、請求項1~4のいずれかに記載の免疫賦活剤。
- 前記CpGオリゴデオキシヌクレオチドがAタイプCpGオリゴデオキシヌクレオチドである、請求項1~5のいずれかに記載の免疫賦活剤。
- 請求項1~6のいずれかに記載の免疫賦活剤を含有する、医薬。
- ワクチン組成物である、請求項7に記載の医薬。
- さらに抗原を含有する、請求項7又は8に記載の医薬。
- 抗ウイルス用である、請求項7~9のいずれかに記載の医薬。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018227061A JP7385206B2 (ja) | 2018-12-04 | 2018-12-04 | 免疫賦活剤 |
JP2023186085A JP2023181377A (ja) | 2018-12-04 | 2023-10-31 | 免疫賦活剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018227061A JP7385206B2 (ja) | 2018-12-04 | 2018-12-04 | 免疫賦活剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023186085A Division JP2023181377A (ja) | 2018-12-04 | 2023-10-31 | 免疫賦活剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020090445A JP2020090445A (ja) | 2020-06-11 |
JP7385206B2 true JP7385206B2 (ja) | 2023-11-22 |
Family
ID=71012367
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018227061A Active JP7385206B2 (ja) | 2018-12-04 | 2018-12-04 | 免疫賦活剤 |
JP2023186085A Pending JP2023181377A (ja) | 2018-12-04 | 2023-10-31 | 免疫賦活剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023186085A Pending JP2023181377A (ja) | 2018-12-04 | 2023-10-31 | 免疫賦活剤 |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP7385206B2 (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007535473A (ja) | 2003-06-26 | 2007-12-06 | カイロン コーポレイション | Chlamydiatrachomatisに対する免疫原性組成物 |
JP2008148556A (ja) | 2005-03-31 | 2008-07-03 | Univ Of Tokyo | インターフェロン−α及び/又はβ(IFN−α/β)の発現誘導を促進する補助剤のスクリーニングする方法 |
JP2010522206A (ja) | 2007-03-22 | 2010-07-01 | ピーディーエス バイオテクノロジー コーポレイション | カチオン脂質による免疫応答の刺激 |
WO2011040535A1 (ja) | 2009-09-30 | 2011-04-07 | 東レ株式会社 | C型肝炎ウイルスワクチン組成物 |
JP2015530423A (ja) | 2012-07-25 | 2015-10-15 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 食器用洗剤、清浄剤、洗浄剤又は水処理用製剤中の添加剤としての、クエン酸をベースにした分枝ポリエステルの使用 |
JP2015530413A (ja) | 2012-09-21 | 2015-10-15 | ベデュ−アッド,フランク | 改良されたワクチン組成物および使用方法 |
JP2017509713A5 (ja) | 2014-07-09 | 2017-08-17 | ||
JP2017524682A (ja) | 2014-06-26 | 2017-08-31 | チャンチュン ファープ バイオテクノロジー カンパニー リミテッド | CpGオリゴヌクレオチドを含む医薬組成物 |
WO2020017590A1 (ja) | 2018-07-19 | 2020-01-23 | 一般財団法人阪大微生物病研究会 | AタイプCpGオリゴデオキシヌクレオチド含有脂質粒子 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201808312YA (en) | 2014-03-25 | 2018-10-30 | The Government Of The Us Secretary Of The Army | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
-
2018
- 2018-12-04 JP JP2018227061A patent/JP7385206B2/ja active Active
-
2023
- 2023-10-31 JP JP2023186085A patent/JP2023181377A/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007535473A (ja) | 2003-06-26 | 2007-12-06 | カイロン コーポレイション | Chlamydiatrachomatisに対する免疫原性組成物 |
JP2008148556A (ja) | 2005-03-31 | 2008-07-03 | Univ Of Tokyo | インターフェロン−α及び/又はβ(IFN−α/β)の発現誘導を促進する補助剤のスクリーニングする方法 |
JP2010522206A (ja) | 2007-03-22 | 2010-07-01 | ピーディーエス バイオテクノロジー コーポレイション | カチオン脂質による免疫応答の刺激 |
WO2011040535A1 (ja) | 2009-09-30 | 2011-04-07 | 東レ株式会社 | C型肝炎ウイルスワクチン組成物 |
JP2015530423A (ja) | 2012-07-25 | 2015-10-15 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 食器用洗剤、清浄剤、洗浄剤又は水処理用製剤中の添加剤としての、クエン酸をベースにした分枝ポリエステルの使用 |
JP2015530413A (ja) | 2012-09-21 | 2015-10-15 | ベデュ−アッド,フランク | 改良されたワクチン組成物および使用方法 |
JP2017524682A (ja) | 2014-06-26 | 2017-08-31 | チャンチュン ファープ バイオテクノロジー カンパニー リミテッド | CpGオリゴヌクレオチドを含む医薬組成物 |
JP2017509713A5 (ja) | 2014-07-09 | 2017-08-17 | ||
WO2020017590A1 (ja) | 2018-07-19 | 2020-01-23 | 一般財団法人阪大微生物病研究会 | AタイプCpGオリゴデオキシヌクレオチド含有脂質粒子 |
Non-Patent Citations (4)
Title |
---|
J.Immunol.,2009年,Vol.183,pp.6186-6197 |
日本薬学会第138年会要旨集,2018年03月25日,Vol.138,27V-pm01S |
第22回日本ワクチン学会学術集会プログラム・要旨集,2018年12月,Vol.22,Page89 1-3-06 |
第62回日本薬学会関東支部大会要旨集,2018年09月,Vol.62,p.174 P-182 |
Also Published As
Publication number | Publication date |
---|---|
JP2023181377A (ja) | 2023-12-21 |
JP2020090445A (ja) | 2020-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240091335A1 (en) | Novel thi-inducing adjuvant comprising combination of different nucleic acid adjuvants and use of same | |
Tagami et al. | CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes | |
Chen et al. | A simple but effective cancer vaccine consisting of an antigen and a cationic lipid | |
US20200016274A1 (en) | Messenger rna vaccines and uses thereof | |
JP5971945B2 (ja) | カチオン性脂質の鏡像異性体による免疫応答の刺激 | |
JP4535211B2 (ja) | コクリエート送達ビヒクル | |
US20190275145A1 (en) | Particulate vaccine formulations | |
CA2876656C (en) | Cationic lipid vaccine compositions and methods of use | |
JP6487850B2 (ja) | アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法 | |
US20240075128A1 (en) | Immunogenic constructs, compositions, and methods for inducing immune response | |
Yu et al. | The immunological adjuvant activity of gypenosides liposome against Newcastle disease vaccine | |
US10182987B2 (en) | Lipid membrane structure for intracellular delivery of siRNA | |
KR20240009419A (ko) | 바이러스 백신 | |
JP7082110B2 (ja) | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット | |
JP7385206B2 (ja) | 免疫賦活剤 | |
WO2016194685A1 (ja) | アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物 | |
JP2024514364A (ja) | 緩衝物質を含むrna組成物ならびにその製造、保存および使用のための方法 | |
Gasparini et al. | Utility of virosomal adjuvated influenza vaccines: a review of the literature | |
WO2020017590A1 (ja) | AタイプCpGオリゴデオキシヌクレオチド含有脂質粒子 | |
WO2023145749A1 (ja) | 免疫賦活剤 | |
WO2024109612A1 (zh) | 一种用于高效递送核酸药物的脂质纳米颗粒的制备方法和应用 | |
EP2060271A1 (en) | Liposome and immunostimulating composition comprising the same | |
CN118265522A (en) | Lipid-based RNA formulations suitable for treatment | |
Moser | Virosomes | |
Badea et al. | Gemini nanoparticles as a co-delivery system for antigen–CpG oligodeoxynucleotide adjuvant combination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221213 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20221220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230516 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231101 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7385206 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |